Pfizer

Activities: Manufacturing Ingredients Research & Development Pharmaceutical Nutraceutical

Trending Articles

  1. Partnering for success: adaptable CDMO solutions for pharma, diagnostics, and biotech When it comes to liquid formulations and freeze-drying (lyophilisation) services, choosing a contract development and manufacturing organisation (CDMO) that prioritises...
  2. RCPE and InSilicoTrials to digitalise and accelerate the development of pharmaceutical manufacturing processes RCPE and InSilicoTrials have agreed to an exclusive partnership to commercialise the XPS simulation software. Specifically developed for pharmaceutical applications, XPS allows...
  3. WHO pandemic agreement determined after three years of negotiation Through the deal, WHO will promote a unified, global response to future pandemics, ensuring that national health systems are equipped to control future outbreaks
  4. Common reasons why field certifiers fail accreditation Biosafety cabinets are the backbone of laboratory safety; however, many facilities encounter significant obstacles when using them, such as high energy consumption,...
  5. Beyond performance: GF’s SYGEF turns 50 PVDF piping systems continue to provide trusted solutions for demanding industries

Upcoming event

Making Pharmaceuticals

29-30 April 2025 | Conference | Coventry, UK See all

Related Content

Research & Development

Pfizer discontinues development of GLP-1 receptor agonist, danuglipron

The oral GLP-1 receptor agonist was discontinued due to reports of potential drug-induced liver toxicity in one patient during phase III trials
Manufacturing

Pfizer integrates Coperion's K-Tron feeders into its German OSD manufacturing plant

Pfizer's contained facility in Freiburg, Germany now includes Coperion's K-Tron feeders, which will dose the correct amount of excipients and APIs required for each batch
Pharmaceutical

Pfizer appoints Chris Boshoff as Chief Scientific Officer and President of R&D

Dr Boshoff will be responsible for overseeing and advancing Pfizer's R&D initiatives across all therapeutic areas
Regulatory

Pfizer gains European Commission approval for haemophilia A and B drug, Hympavzi

The subcutaneous therapeutic is the first and only anti-tissue factor pathway inhibitor approved for the treatment of haemophilia A or B, and is available in an auto-injector format
Regulatory

Pfizer's haemophilia A/B therapeutic Hympavzi gains FDA approval

The pharma giant's once-weekly injectable can be administered subcutaneously and is able to significantly reduce annualised bleeding
Regulatory

Tivdak receives US FDA approval for treating recurrent cervical cancer

The full approval of tisotumab vedotin will offer a treatment for patients with metastatic or recurrent cervical cancer exhibiting disease progression on or after chemotherapy
Manufacturing

Samsung Biologics and Pfizer's collaboration for manufacturing of biosimilars

Under the terms of the new agreement, Samsung Biologics will provide Pfizer with additional capacity for large-scale manufacturing for a multi-product biosimilars portfolio
Subscribe now